Advanced Accelerator Applications: Clinical Trials

39 trials sponsored by Advanced Accelerator Applications, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 8 terminated, 6 recruiting, 5 active not recruiting. 22 Phase 2, 13 Phase 1, 3 Phase 3, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 222Terminated 7, Completed 5, Recruiting 4, Active not recruiting 2, Unknown 2, Suspended 1, Withdrawn 1
Phase 113Completed 6, Terminated 4, Active not recruiting 1, Recruiting 1, Withdrawn 1
Phase 33Completed 2, Active not recruiting 1
Phase 41Completed 1

Follow Advanced Accelerator Applications: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Phase 2RecruitingOHSU Knight Cancer Institute102026-06-302026-06-05
Radiopharmaceutical Treatment of Advanced Kidney Cancer
177Lu-PSMA-617 - Metastatic Clear Cell Renal Cell Carcinoma
Phase 2RecruitingEuropean Organisation for Research and Treatment of Cancer - EORTC482026-04-072026-06-04
Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer
[177Lu]Lu-PSMA-617, Ipilimumab - Very High Risk Prostate Carcinoma
Phase 1 / Phase 2TerminatedUniversity Hospital, Essen12025-08-252026-03-13
Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in
77 Lu-DOTA0-Tyr3-Octreotate - Metastatic Nasopharyngeal Cancer
Phase 2SuspendedNational Cancer Centre, Singapore252023-05-052026-05-22
Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)
Liquid Biopsy, Archival Tumor DNA sequencing - Metastatic Prostate Cancer
RecruitingSOLTI Breast Cancer Research Group2402023-03-282025-08-06
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Cabozantinib, Lu-177 - Neuroendocrine Tumors
Phase 1Active not recruitingProvidence Health & Services62022-12-282026-04-13
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Lutetium [177Lu] oxodotreotide/dotatate - Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Phase 2Active not recruitingAdvanced Accelerator Applications112022-08-312026-02-12
EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
177Lu-PSMA-617, Ipilimumab, Nivolumab - Prostatic Neoplasms, Genital Neoplasms, Male
Phase 2UnknownAustralian and New Zealand Urogenital and Prostate Cancer Trials Group932022-04-292023-12-15
Lutathera and ASTX727 in Neuroendocrine Tumours
ASTX727, Lutathera - Neuroendocrine Tumors
Phase 1RecruitingImperial College London372022-04-252026-11-12
EBRT + Lu-PSMA for N1M0 Prostate Cancer
177Lu-PSMA-617, EBRT - Prostatic Neoplasm
Phase 1CompletedThe Netherlands Cancer Institute142021-12-202025-12-10
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection, Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection, LUTATHERA® by intra-arterial hepatic (IAH) injection - Neuroendocrine Tumor, Liver Metastases
Phase 2RecruitingUniversity Hospital, Bordeaux232021-09-242025-07-23
177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
177Lu-DOTATATE - Neuroblastoma Recurrent, Neuroblastoma
Phase 2RecruitingJakob Stenman242021-05-192026-11-09
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
arginine/lysine - Gastroenteropancreatic Neuroendocrine Tumors
Phase 4CompletedAdvanced Accelerator Applications422021-01-252025-01-24
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
Lutathera - Carcinoid Heart Disease, Carcinoid Syndrome
Phase 2UnknownKing's College Hospital NHS Trust202020-10-012020-08-04
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
177Lu-DOTA-tyr3-OCTREOTATE, Peptide Receptor Radiotherapy (PRRT) - Neuroendocrine Tumors, Pheochromocytoma
Phase 1 / Phase 2WithdrawnSue O'Dorisio2020-08-042021-06-08
Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer
177Lu-PSMA-617 - Prostate Cancer
Phase 2CompletedRadboud University Medical Center582020-07-202026-02-27
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
177Lu-DOTA-TATE + olaparib - Clinical Trial, Phase I, Neuroendocrine Tumors
Phase 1CompletedVastra Gotaland Region182020-04-232026-04-14
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
177Lu-PSMA-617, Docetaxel - Metastatic Hormone Naive Prostate Cancer
Phase 2Active not recruitingPeter MacCallum Cancer Centre, Australia1302020-04-212025-07-11
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution - Gastro-enteropancreatic Neuroendocrine Tumor
Phase 3Active not recruitingAdvanced Accelerator Applications2262020-01-082026-01-21
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
68Ga-DOTATATE, Positron Emission Tomography (PET) Scan - Neuroendocrine Carcinoma
CompletedH. Lee Moffitt Cancer Center and Research Institute302019-09-252026-03-31

Showing 20 of 39. Sign in to see all of them.

Conditions studied

Neuroendocrine Tumors (9)  ·  Prostatic Neoplasms (8)  ·  Neoplasms (5)  ·  Breast Neoplasms (3)  ·  Gastro-enteropancreatic neuroendocrine tumor (3)  ·  Genital Neoplasms, Male (3)  ·  Neoplasms by Site (3)  ·  Prostatic Diseases (3)  ·  Urogenital Neoplasms (3)  ·  Carcinoid Tumor (2)  ·  Paraganglioma (2)  ·  Pheochromocytoma (2)  ·  Small Cell Lung Carcinoma (2)  ·  Spondylitis, Ankylosing (2)  ·  Arthritis, Psoriatic (1)

Interventions

lutetium Lu 177 dotatate (13)  ·  Pluvicto (6)  ·  Ipilimumab (2)  ·  Lutetium-177 (2)  ·  Nivolumab (2)  ·  Octreotide (2)  ·  gallium Ga 68 dotatate (2)  ·  Biopsy (1)  ·  Docetaxel (1)  ·  Ga(III)-DOTATOC (1)  ·  Injections (1)  ·  Liquid Biopsy (1)  ·  Lutetium (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  PSMA-11 (1)

Countries

United States (15)  ·  France (10)  ·  United Kingdom (9)  ·  Spain (8)  ·  Netherlands (6)  ·  Canada (4)  ·  Germany (3)  ·  Italy (3)  ·  Australia (2)  ·  Austria (2)  ·  Poland (2)  ·  Portugal (2)  ·  Sweden (2)  ·  Switzerland (2)  ·  Belgium (1)

Top investigators

Arun Azad, MBBS PhD FRACP (1)  ·  Chul Kim, MD (1)  ·  Daniel Tan, BSc, MBBS, PhD (1)  ·  Dominique Le Guludec, MD, PhD (1)  ·  Emmanuel Seront, MD (1)  ·  Hagen Kennecke, MD (1)  ·  Jakob Stenman, MD PhD (1)  ·  James Nagarajah, Prof. (1)  ·  John O Prior, PhD MD (1)  ·  John Prior, MD, PhD (1)  ·  Jonathan Strosberg, MD (1)

Results publications

PMID 28076709, PMID 29878866, PMID 32123969, PMID 32616557, PMID 32928177, PMID 33189510, PMID 33973550, PMID 34736509, PMID 34793718, PMID 34829796, PMID 35359899, PMID 36959540, PMID 37879695, PMID 38753757, PMID 38851203, PMID 39293461, PMID 39570708, PMID 39915126, PMID 40198358, PMID 40473457, PMID 41073165, PMID 41926960, PMID 42225102, PMID 42604001

NIH funding

2023 (3), 2017 (2), 2019 (2), 2009 (1)